Daniela Barbero

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi

Carlo Visco, Annalisa Chiappella, Luca Nassi et al. · The Lancet Haematology · 2016 · 138 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study

Simone Ferrero, Davide Rossi, Andrea Rinaldi et al. · Haematologica · 2019 · 135 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma

Daniela Drandi, Lenka Kubiczkova-Besse, Simone Ferrero et al. · Journal of Molecular Diagnostics · 2015 · 132 citations · Full text

Medicine, Hematology, Oncology +17

Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma

Simone Ferrero, Luigia Monitillo, Barbara Mantoan et al. · Annals of Hematology · 2013 · 20 citations

Medicine, Immunology, Oncology +12

Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma

Chiara Lobetti‐Bodoni, Barbara Mantoan, Luigia Monitillo et al. · Therapeutic Advances in Hematology · 2013 · 19 citations · Full text

Medicine, Hematology, Oncology +13